Help us to identify the evolving needs in advancing cell and gene therapy products in Australia. Click here to complete the survey 

The TIA Consortium is a national network of leading translational research infrastructures across three capabilities - Biologics & Vaccines, Cell & Gene Therapies and Small Molecule Pharmaceuticals. We provide access to expertise and services to assist researchers and SMEs in the development of new therapeutic products.


TIA has developed initiatives
to help you find the expertise and services you need


Pipeline Navigator

Find the right facility using our online map of the drug R&D pipeline


Pipeline Accelerator

Apply for vouchers to assist in accessing TIA facilities



Tailored advice on development of hit compounds from screening



Free download of generic quality system documents


"These results from the CDCO bolster the already well-developed case for advancing inhalational drug candidates through a development program, and have accelerated interest in advancing alternative candidates forward for oral treatment of assorted fibrotic conditions. The value for the research program is immense through allowing us to focus our future resources on the most promising compounds."

Prof Alistair Stewart,
University of Melbourne

"The outcome of the screen is to demonstrate that tumours with over-active AURKA-PLK1 pathway are likely to be sensitive to drugs targeting replication stress, a class of drugs we have found to have highly effective anti-tumour activity and very little normal tissue toxicity"

Prof Brian Gabrielli,
Mater Research

“Kathleen has produced an exceptionally high quality screening project that has clear clinical implications. The project was delivered exactly as we had imagined, we added some advanced elements to the imaging and the analysis that were value-add technology applications that had evolved subsequent to the TIA application.”

A/Prof Kaylene Simpson,
Victorian Centre for
Functional Genomics

“The outcomes from the TIA funded research are critical because they now allow the team to move forward confidently with an antibody for clinical use in ovarian cancer patients.”

Dr Martina Jones, 
National Biologics Facility


“The data from this project will form a strong foundation for the development of new therapeutic products and, given the insufficient availability of cardioprotective molecules, further development should be
commercially viable"

Prof. Jonathan Baell,
Australian Translational Medicinal Chemistry Facility

“The professionalism of the researchers at ATMCF has inspired us to further invest and move forward in bettering our synthesis methods and yield.”

Mr Greg Santamaria,
Cyclotek Pty Ltd